• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Sohini Chowdhury, 2011
 

Sohini Chowdhury, 2011

on

  • 557 views

Michael J Fox

Michael J Fox

Statistics

Views

Total Views
557
Views on SlideShare
375
Embed Views
182

Actions

Likes
0
Downloads
0
Comments
0

14 Embeds 182

http://disruptiveinnovationsinclinicaltrials.blogspot.com 146
http://disruptiveinnovationsinclinicaltrials.blogspot.co.uk 8
http://disruptiveinnovationsinclinicaltrials.blogspot.com.br 5
http://disruptiveinnovationsinclinicaltrials.blogspot.in 5
http://disruptiveinnovationsinclinicaltrials.blogspot.com.au 4
http://disruptiveinnovationsinclinicaltrials.blogspot.nl 3
http://disruptiveinnovationsinclinicaltrials.blogspot.com.es 2
http://disruptiveinnovationsinclinicaltrials.blogspot.ca 2
http://disruptiveinnovationsinclinicaltrials.blogspot.be 2
http://disruptiveinnovationsinclinicaltrials.blogspot.pt 1
http://disruptiveinnovationsinclinicaltrials.blogspot.fr 1
http://disruptiveinnovationsinclinicaltrials.blogspot.co.il 1
http://disruptiveinnovationsinclinicaltrials.blogspot.co.at 1
http://disruptiveinnovationsinclinicaltrials.blogspot.gr 1
More...

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Sohini Chowdhury, 2011 Sohini Chowdhury, 2011 Presentation Transcript

    • Public-Private Partnership Model: The Parkinson’s Progression Markers Initiative •Sohini Chowdhury, Vice President, Research Partnerships Sept 16, 2011
    • Parkinson’s is a global disease and prevalence is growing  Parkinson’s disease (PD) is a progressive neurodegenerative disease that affects nearly six million worldwide.  PD prevalence is expected to grow sizably over the next 25 years as the proportion of older citizens continues to increase globally.  Current therapies address mild/moderate motor symptoms  There is currently no therapy proven to modify – slow or halt – the progression of the disease. 2
    • Drug development is a lengthy and costly process Takes ~15 years for drug therapy to go through R&D and get to market ~8 of those years are spent in clinical testing 3
    • Clinical testing of PD therapies is challenging  Obstacles include: • Current trial paradigm requires large number of subjects • Efficacy testing is a long process, diminishing patent value • Reliance on clinical measures alone confound trial interpretation • There are no biological indications of underlying disease that complement clinical changes Increases risk for pharma, the main sponsors of therapeutic trials
    • The Parkinson’s Progression Markers Initiative (PPMI) PPMI is a ground-breaking clinical study that aims to accelerate PD drug development by identifying biomarkers of Parkinson’s Disease
    • Critical to PPMI’s success is recruiting a cohort of 600 21 sites in Europe and US are recruiting subjects; soon to be expanded to Australia 6
    • Various groups provide input/management of study facets 7
    • Industry is a valuable partner
    • A strong emphasis on standardization and sharing SOPs 9
    • A strong emphasis on recruitment PPMI Enrollment Status As of Sept 2011 10
    • Data made available and shared in real-time via study website 11